Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Breast Neoplasms 2Vomiting 1Uterine Cervical Neoplasms 1Trigger Finger Disorder 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pain 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Nausea 1Mucositis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Mast-Cell 1Leukemia, Hairy Cell 1

Interventions

isatuximab 2Dexamethasone 2pomalidomide 1Ranitidine 1Lenalidomide 1Diphenhydramine 1Cyclophosphamide 1CLR1404 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Blood Protein Disorders × Acetaminophen × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡